Hot Stocks: Lincoln National Corporation(NYSE:LNC), Starwood Hotels & Resorts Worldwide, Inc(NYSE:HOT), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Lakeway, NY -- (SBWIRE) -- 03/19/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Lincoln National Corporation(NYSE:LNC) shares fell 1.82% to $ 32.83.Thecompany’s Retirement Plan Services business has engaged the Retirement Income Team of law firm Drinker Biddle & Reath LLP to create resources designed to help plan sponsors better understand and assess the value in-plan guarantees can add to employer-sponsored retirement plan programs.

Additionally, the company, on Mar. 5, announced the introduction of its Lincoln Treasury Indexed Universal Life (IUL) solution designed to capture the benefits of a potential rise in interest rates.

Get Latest News, Updates on LNC Here

Starwood Hotels & Resorts Worldwide, Inc(NYSE:HOT) shares fell 1.80% to $ 62.18. The company, on Mar. 14, announced that President & CEO Frits van Paasschen, Vice Chairman & CFO Vasant Prabhu and other senior members of the Company's leadership are presenting Starwood's business strategy, key initiatives and three-year financial outlook during its Investor & Analyst Day held today in Dubai.

Additionally, the company, on Mar. 6, announced that, with a continued focus on growth in Latin America, the company aims to have 100 hotels under operation and development in Latin America by the end of 2013. Currently, Starwood has a strong footprint of 71 hotels in 13 countries, and a robust development pipeline of 20 hotels with a total 3,300 new rooms underway.

Is HOT a Strong Buying Opportunity After The Recent Slump? Find out Here

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares dropped 1.80% and closed at $51.37. VRTX‘s stock had its “sell” rating restated by equities researchers at TheStreet in a report issued on Mar. 4.

Additionally, the company, on Mar. 4, announced that treatment with VX-787 in a Phase 2 influenza challenge study resulted in statistically significant improvements in viral and clinical measurements of infection. VX-787 is an investigational new class of medicine for the treatment of influenza and is designed to directly inhibit replication of the virus.

Is VRTX Signaling a Buy After The Sudden Slump? Don’t Miss Out Free Trend Analysis Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.